ASITI (Antigen Specific Immune Tolerance Induction) nanoparticle technology in Phase 1b study and subsequent reverse translation studies elucidate dosing strategy to optimize the expansion of regulatory T cells for tolerance.

Targets self-antigen which is the underlying cause of the autoimmune disease rather than treating the symptoms alone and hampering the immune system’s ability to fight infections.  UniQuest is seeking a partner to help prioritise and develop one or more therapeutic programs such as type 1 diabetes, rheumatoid arthritis and other autoimmune diseases.

Contact us

To enquire about this technology, please contact us.